Return to News Categories

Commentary and Educational Cattle - Hogs / Livestock News Currencies News Energy News Grain News Index News Interest Futures News Metals Futures News Reports: Crops, CFTC, etc Soft Commodities News

Futures and Commodity Market News

Australia : Bod delivers strong first half performance

Mar 07, 2018 (Euclid Infotech Ltd via COMTEX) --

Developer and distributor of natural, evidence-based cosmetics and natural medicines and health products. Bod Australia Limited ("Bod" or the "Company") is pleased to provide its Half Year (HI) financial report for the period ending 31 December 2017. The period has been one of significant growth for the Company.

During the first half, revenues from ordinary activities have surged 196.4% to $725,228 from the previous corresponding period (PCP). The significant increase in revenues is attributed to a number of factors and milestones achieved by the Company throughout the period.

During HI, the Company has nearly tripled its total number of 'doors', or individual pharmacies, chemists, department stores or specialty retailers that stocks Bod's products from 325 to 944. Through the Company's agreements with groups such as API, Priceline Pharmacy and David Jones amongst others. Bod will continue to leverage its current channels to market and further grow this distribution footprint. Currently, the Company has products represented in 944 doors and is continuing discussions with a range of banner groups and retailers to increase this and generate further revenues across the second half.

Further underpinning revenues during the half and as announced 13 December 2017, Bod commenced sales into lucrative Asian markets such as China. These sales were achieved through the Company's key Daigou relationships. A Daigou is channel of commerce In which an entity from outside of China purchases commodities for an individual or group in Mainland China. Management are pleased to advise that they are witnessing a strong pipeline of orders from Daigou buying agents and additional revenues will be realised from these channels across the remainder of the financial year.

Throughout the period, the Company considerably enhanced its natural medicines, health and cosmetic product suites. As announced 8 November 2017, Bod secured the exclusive distribution rights to Mamacare. Mamacare's range includes a pharmaceutical-grade, milk-based supplement powder that contains all nutrients that women require before, during and after pregnancy. Under the agreement Bod will manage all key aspects of Mamacare's distribution, marketing and sales in Australia, New Zealand and China.

While the Company has begun to realise revenues from the introduction of the new brands, it is pleased to advise a strong order pipeline Is building and additional revenues are expected to be generated across the remaining half.

In an additional development and subsequent to the end of the period, the Company also entered into an exclusive Heads of Agreement with Manuka Pharma for the development, manufacture supply of a hemp-based, high methylglyoxal (MGS) Manuka honey product line.

Through the agreement. Manuka Pharma will source, manufacture and develop the product, while Bod will import it into Australia for packaging under the Company's brands and logos. The finished product is expected to launch in quarter 4 with revenue and sales to follow shortly thereafter.

Please read the End User Agreement.
By accessing this page, you agree to the terms and conditions of the End User Agreement.

News provided by COMTEX.

Lt Crude 62.25
Nat Gas 2.696
Corn 382 6/8
Cotton #2 82.85
Gold 1313.9
Copper 3.1125
Euro 1.22920
USD Index 90.212
SP500 E-mini 2755.50
DJIA E-mini 24965